Form 483

Otsuka ICU Medical LLC Form 483, 2017-03-10

FDA issued a Form 483 to Otsuka ICU Medical LLC on 2017-03-10 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

Otsuka ICU Medical LLC · Austin, United States · Issued March 10, 2017

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

10 Mar 2017
21 CFR 211.160(a)

Deviations from laboratory control requirements

Cited by Shawn E Larson, Margaret M Annes, Shatina R Alridge

10 Mar 2017
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Shawn E Larson, Margaret M Annes, Shatina R Alridge

10 Mar 2017
21 CFR 211.165(e)

Test methods

Cited by Shawn E Larson, Margaret M Annes, Shatina R Alridge

10 Mar 2017
21 CFR 211.198(a)

Procedures to be written and followed

Cited by Shawn E Larson, Margaret M Annes, Shatina R Alridge

10 Mar 2017
21 CFR 211.68(b)

Computer control of master formula records

Cited by Shawn E Larson, Margaret M Annes, Shatina R Alridge

Inspected site

OIOtsuka ICU Medical LLCAustin, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere